BIOTECHNOLOGY company Silence Therapeutics has appointed Tim Freeborn as FD.
Freeborn qualified as a chartered accountant with Arthur Goddard & Co, specialising in corporate tax. He then spent 12 years as a finance journalist at the Daily Mail before spending two years editing the Penny Shares Guide. He also wrote part-time for Shares Magazine.
In 2004, Freeborn joined Evolution Securities as an analyst, focusing on renewables and alternative energy, before he joined Xcap Securities in 2009, becoming head of research.
"Silence's area of biotech is moving incredibly quickly. The company could play a big role and I'm delighted to be joining at this time," he said.
You may also like
If budgeting is to have any value at all, it needs a radical overhaul. In today's dynamic marketplace, budgeting can no longer serve as a company's only management system; it must integrate with and support dedicated strategy management systems, process improvement systems, and the like. In this paper, Professor Peter Horvath and Dr Ralf Sauter present what's wrong with the current approach to budgeting and how to fix it.
In this white paper CCH provide checklists to help accountants and finance professionals both in practice and in business examine these issues and make plans. Also includes a case study of a large commercial organisation working through the first year of mandatory iXBRL filing.